Verified employee & interview reviews

Fortrea Reviews

Durham, North Carolina

4.3/ 5

3 reviews

Fortrea Holdings Inc. is a leading global contract research organization (CRO) that provides comprehensive clinical development and patient access solutions to the life sciences industry. Headquartered in Durham, North Carolina, the company officially became an independent, publicly traded entity on July 3, 2023, following its spin-off from Laboratory Corporation of America Holdings (LabCorp). Although newly independent, Fortrea carries a legacy of over 30 years of product development expertise, tracing its roots through LabCorp’s drug development division and the well-known CRO Covance. The company's core mission is to partner with emerging and large biopharmaceutical, medical device, and diagnostic companies to accelerate the delivery of life-changing therapies. Fortrea’s operations span the entire clinical trial spectrum, from Phase I through Phase IV. Its service offerings include clinical pharmacology, study management, clinical trial execution, and post-approval services. By leveraging its extensive investigator site network and deep therapeutic expertise—particularly in oncology, rare diseases, and central nervous system disorders—Fortrea helps sponsors navigate complex regulatory landscapes and streamline the drug development process. Functionally, Fortrea operates under several delivery models to meet diverse client needs. These include full-service provider (FSP) arrangements, where the company manages all aspects of a clinical trial, and functional service models, where sponsors hire dedicated teams for specific tasks such as biostatistics, pharmacovigilance, medical writing, or regulatory support. The company also maintains specialized Phase I clinical pharmacology units focused on drug safety, tolerability, and pharmacokinetics. Innovation and technology are central to Fortrea’s strategy. The company utilizes data-enabled trial solutions and digital platforms to improve site selection, enrollment forecasting, and operational transparency. This focus on "technology-enabled" trials aims to reduce cycle times and enhance decision-making for sponsors. Since its spin-off, a major strategic priority has been establishing its own independent enterprise systems and infrastructure to ensure operational agility and data security. With a diverse global workforce of approximately 19,000 employees operating in more than 90 countries, Fortrea is scaled to manage multi-country, highly regulated trials while remaining nimble enough to provide customized solutions. The leadership team, led by CEO Tom Pike, emphasizes a patient-centric approach and a culture of scientific rigor. In fiscal year 2024, the company reported significant consolidated revenue, reflecting its position as a major player in the global CRO market. By integrating Environmental, Social, and Governance (ESG) frameworks and focusing on diversity and inclusion, Fortrea aims to reflect the communities it serves while driving sustainable growth in the healthcare innovation sector.